Mingshu Zhang: Cyclic peptide engineering for ACPA research in rheumatoid arthritis: From epitope stabilization to fine specificity profiling

Datum
20 november 2026, kl. 9.00
Plats
Lecture Hall IV, University Main Building, Biskopsgatan 3, Uppsala
Länk till videomöte
https://uu-se.zoom.us/j/65872730266
Typ
Disputation
Respondent
Mingshu Zhang
Opponent
Gunnar Houen
Handledare
Ulf Göransson
Forskningsämne
Farmaceutisk vetenskap
Publikation
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-600503

Abstract

Antibodies, proteins, and peptides remain important classes in modern drug development due to their target specificity and ability to modulate biological processes. However, structural complexity and limited stability are challenging for their applications. Autoantigen-derived peptides have been proposed as potential autoantibody scavengers, but a major limitation of peptide-based therapeutics is their poor stability in vivo. This thesis aimed to develop stable engineered cyclic peptides mimicking autoantigen epitopes in rheumatoid arthritis (RA) and to investigate their applications in autoantibody fine specificity characterization and diagnostic profiling.

In Paper I, five structurally diverse cyclic peptides from the PawS-derived peptide (PDP) family were investigated as scaffolds for molecular grafting, resulting in ten engineered peptides targeting anti-citrullinated protein/peptide antibodies (ACPAs). The grafted peptides showed significantly improved stability in human serum compared with their corresponding linear epitopes while maintaining ACPA binding, supporting PDPs as promising scaffolds for epitope presentation. Importantly, the results showed that the scaffold is not just a carrier, as epitope-scaffold compatibility can directly influence epitope presentation and antibody recognition.

In Paper II, a large-scale IgG purification workflow was established for ACPA characterization at individual-level. Engineered peptides representing six autoantigen epitopes, together with one commercial peptide, were used to isolate seven fine specific ACPA populations from eight RA patients and to develop peptide-specific ELISAs. Comparison across affinity purification, ELISA, peptide-array, and other analytical methods revealed substantial inter-individual heterogeneity in ACPA fine-specificity and cross-reactivity. ACPAs isolated using the same peptide showed partially overlapped cross-reactivity profiles between patients, while differences across assay platforms highlighted the influence of epitope presentation. These findings support that ACPA repertoire may act as an interconnected pool of antibody populations with preferred epitopes but varying degrees of cross-reactivity.

Paper III translated the peptide-specific ELISA into an electrochemiluminescence-based assay for ACPA fine specificity profiling. Cohort-based evaluation provided information beyond conventional serological testing, including additional reactivity in some seronegative RA patients, although the overall improvement in disease classification was modest. Fine specificity profiling may therefore complement the conventional anti-CCP assay.

Taken together, this thesis demonstrates the potential of cyclic peptide engineering to generate stable epitope-presenting tools for resolving the multidimensional heterogeneity of ACPA and exploring its machanisms.